Culturing adequate CAR-T cells from less peripheral blood to treat B-cell malignancies.

Lu HanJian ZhouLinlin LiKeshu ZhouLingdi ZhaoXinghu ZhuQingsong YinYufu LiHongqin YouJishuai ZhangYongping SongQuan-Li Gao

Published in: Cancer biology & medicine (2021)

Our novel method can generate sufficient numbers of CAR-T cells for clinical use from 50-100 mL peripheral blood, thus providing an alternative means of CAR-T cell generation for patients ineligible for leukapheresis.

Keyphrases

peripheral blood
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
peritoneal dialysis
patient reported